25 LLC’s Neurocrine Biosciences NBIX Stock Holding History

25 LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$481	–	363
2023 Q2	$481	Hold	5	–	–	﹤0.01%	568
2023 Q1	$490	Buy	+5	New	+$520	﹤0.01%	406

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

25 LLC's NBIX Position: Q3 2023 in Review

25 LLC sold out of Neurocrine Biosciences (NBIX) in Q3 2023, closing a stake of 5 shares — an estimated $481 sold.

25 LLC first reported a position in NBIX in Q1 2023 and held it in 2 quarters. The position peaked at $490 in Q1 2023. 511 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

25 LLC reported no remaining Neurocrine Biosciences position as of Q3 2023 after selling out during the quarter.
25 LLC sold 5 Neurocrine Biosciences shares in Q3 2023, an estimated $481.
25 LLC first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 2 quarters.
25 LLC's Neurocrine Biosciences position peaked at $490 in Q1 2023.
511 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.